NanoViricides Inc (NNVC)

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Form 424B3 - Prospectus [Rule 424(b)(3)]

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher

SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and...

Form EFFECT - Notice of Effectiveness

Form DEL AM - Delaying amendment

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced that it has...

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Form S-3 - Registration statement under Securities Act of 1933

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides

SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Form 8-K - Current report

Form 8-K - Current report